Timothy J. Shea, Director, Sterne, Kessler, Goldstein & Fox, to Speak at TKG's Understanding the BPCIA Litigation Pathway LIVE Webcast
The Knowledge Group, the leading producer of regulatory focused webcasts, has announced today that Timothy J. Shea, Director, Sterne, Kessler, Goldstein & Fox P.L.L.C. will speak at The Knowledge Group’s webcast entitled: “Understanding the BPCIA Litigation Pathway Amidst the Increasing Biosimilar Disputes LIVE Webcast”.
- New York, NY (1888PressRelease) October 24, 2017 - This event is scheduled for November 6, 2017 from 12:00 PM - 2:00 PM (ET).
For further details, please visit:
https://www.theknowledgegroup.org/webcasts/legal/intellectual-property-law/understanding-the-bpcia-litigation-pathway
About Timothy J. Shea
Tim Shea is Director in the Biotechnology/Chemical Practice Group at Sterne, Kessler, Goldstein & Fox P.L.L.C., where he has practiced for more than 20 years. Mr. Shea specialises in advising biopharmaceutical companies and research institutions on complex legal issues relating to the protection, enforcement, and transfer of their intellectual property. He practices primarily in the fields of immunology, molecular biology, genetic and medical diagnostics, biotherapeutics, and drug delivery. Mr. Shea has extensive experience advising clients on the creation and management of strategic patent portfolios, freedom-to-operate and patentability issues, complex prosecution strategies, validity and infringement issues, and due diligence investigations in connection with acquisitions and investments. He has published and spoken extensively on IP issues related to therapeutic antibodies and biosimilars. In addition, a significant portion of his practice involves counseling emerging companies on strategies for creating, protecting, and leveraging their IP assets to grow their businesses.
Mr. Shea’s full professional biography is available online at the following link: http://www.skgf.com/timothyshea
About Sterne, Kessler, Goldstein & Fox P.L.L.C.
Sterne, Kessler, Goldstein & Fox is an intellectual property law firm of 170+ professionals devoted solely to providing outstanding patent, trademark, Patent Office litigation, district court, and International Trade Commission legal services.
For more than 36 years, Sterne, Kessler, Goldstein & Fox helped companies build and enforce worldwide IP portfolios. Sterne Kessler has a proven track record at U.S. district courts, federal appeals courts, and the International Trade Commission, with worldwide oppositions, 175+ inter partes reviews, 50+ interferences, 400+ reexaminations, and covered business method patent reviews. They are the leader in both inter partes reviews and covered business method reviews in the biotech and pharmaceutical industry.
Sterne Kessler provides a full range of IP services, including: Patent preparation and prosecution, including management of worldwide prosecution, patent Office litigation, including oppositions, reexaminations, interferences, inter partes reviews (IPR), and covered business method (CBM) proceedings, patent litigation in U.S. district courts, state courts, the United States Court of Appeals for the Federal Circuit, and the United States International Trade Commission, strategic patent portfolio development and portfolio management, patent searching conducted at Sterne Kessler, as well as searching by vendors managed by Sterne Kessler, opinions on patentability, freedom to operate, patent infringement, and patent validity, advice on licensing, technology transfer, commercialization, monetization and due diligence; a number of their attorneys are Certified Licensing Professionals: Copyrights, Trademarks and Design Patents.
Event Synopsis:
The Biologics Price Competition and Innovation Act (BPCIA) encourages competition and innovation in the biologics market by providing an abridged pathway for the approval of a biosimilar license application along with a twelve-year market exclusivity. The BPCIA also determines patent infringement disputes by setting out a process and addresses potential litigation following a license application. To streamline biosimilar litigation, the BPCIA implements patent statutes that introduce a new artificial patent infringement act, requires information exchange cycles, envisions two waves of litigation, and restricts patent declaratory judgment actions under certain conditions.
Biosimilar litigation is expected to rise as the number of drug manufacturers considering the addition of biosimilars to their drug product portfolios, continues to grow. To dodge costly pitfalls and irreversible mistakes, a complete understanding of the BPCIA litigation pathway should be considered.
The Knowledge Group has assembled a panel of key thought leaders and professionals to help the audience better comprehend the BPCIA Litigation landscape amidst the increasing Biosimilar Disputes. This panel will also present an in-depth analysis and understanding on the current issues surrounding biosimilar litigation and will provide the audience with practical strategies in bringing out the best in these lawsuits in a rapidly evolving legal climate.
Key topics include:
• An Overview of the BPCIA
• The BPCIA Litigation Pathway
• Notable Cases
• Practical Litigation Strategies
• Trends, Developments and Updates
About The Knowledge Group, LLC/The Knowledge Congress Live Webcast Series
The Knowledge Congress was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register to an event, please visit: http://theknowledgegroup.org/
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam